Aug. 3 Quick Takes: BeiGene picks N.J. for new campus
Plus Zentera, Iterative Scopes, BMS, Novartis, Mestag, Engrail, AbCellera-Tachyon, Outlook
BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) will begin scouring New Jersey and environs for talent to staff its forthcoming new campus at the Princeton West Innovation Campus in Hopewell, N.J., where the Chinese oncology company will build a facility that includes commercial-stage biologic pharmaceutical manufacturing, clinical R&D, and the BeiGene Center for Pharmacovigilance Innovation. BeiGene plans to rent space nearby and begin hiring, with construction expected to be completed in mid-2023.
A $75 million series B round will allow Zentera Therapeutics to advance a trio of oncology assets discovered by parent company Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) as well as BD to in-license additional assets for development in China. Founding investors OrbiMed Advisors Asia and Tybourne Capital Management led the round for the Shanghai- and Beijing-based biotech; they were joined by Avidity Partners, Casdin Capital, Citadel’s Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors in the syndicate. The lead candidates for Zentalis, which was formed by Zentera to develop cancer therapies in China, are WEE1 inhibitor ZN-c3, its oral SERD ZN-c5, and its BCL-2 inhibitor ZN-d5...